Literature DB >> 25829952

Management of idiopathic retroperitoneal fibrosis from the urologist's perspective.

Surcel Cristian1, Mirvald Cristian1, Pavelescu Cristian1, Gingu Constantin1, Carmen Savu2, Emre Huri3, Ioanel Sinescu1.   

Abstract

INTRODUCTION: Idiopathic retroperitoneal fibrosis (IRF) is a rare disease characterized by a fibrotic reaction that affects retroperitoneal organs, especially the urinary tract. In this review we analyze the current imaging techniques, morphological characteristics, clinical aspects and therapeutic aspects of idiopathic retroperitoneal disease.
METHODS: A PubMed search was conducted in December 2013 to find original articles, bibliographic reviews and series reports published in the past 15 years on idiopathic retroperitoneal fibrosis, its management and outcomes by combining terms like retroperitoneal fibrosis, periaortitis, treatment and autoimmune. A total of 89 articles were included in this review that referred strictly to IRF. We analyzed the imaging tools used for diagnostic and the decision making protocol used by physicians in the management of IRF.
RESULTS: A computerized tomography (CT) scan represents the most commonly used imaging technique for diagnosis. Magnetic resonance imaging (MRI) is unable to differentiate more accurately between benign and malignant retroperitoneal fibrosis (RF) than a CT scan. Biopsy remains the most reliable diagnostic tool for IRF. However, the histological characteristics of IRF are not yet well-defined and the protocol for biopsy is not standardized in terms of template, number of biopsies and the immunohistochemical panel needed for positive diagnosis. The most common treatment reported is corticosteroid therapy alone or in combination with other immunosuppressants, whereas surgical treatment is reserved for severe cases. Indwelling ureteric stents represent the most common procedure for renal drainage, but their efficacy is questionable. Open ureterolysis remains the gold standard for surgical treatment, but its purpose is only to resolve the ureteric obstruction, not to treat the retroperitoneal fibrosis. Laparoscopic and robotic approaches have been reported to be feasible, but no prospective, comparative trials have been performed due to the rarity of the disease. Surgical technique is not standardized and the outcome of the treatment only evaluates the recovery of the renal function.
CONCLUSIONS: The imaging procedures available today are unable to accurately differentiate between idiopathic and malignant RF. A biopsy is mandatory to confirm the diagnosis, but there is no consensus regarding the template, timing and number of biopsies needed to exclude malignancy. Open ureterolysis represents the main surgical treatment for cases with severe IRF, and laparoscopic or robotic approach may be an option in selected cases. The recovery of the renal function is a surrogate for evaluating the success of the treatment. More clinical studies are needed in order standardize the protocol for diagnostic, treatment and follow up after medical or surgical management.

Entities:  

Keywords:  differential diagnosis; idiopathic retroperitoneal fibrosis; medical treatment; retroperitoneal biopsy; surgical treatment; ureterolysis

Year:  2015        PMID: 25829952      PMCID: PMC4372523          DOI: 10.1177/1756287214565637

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  91 in total

1.  Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases.

Authors:  Renzo Marcolongo; Ivan Matteo Tavolini; Francesco Laveder; Moira Busa; Franco Noventa; Pierfrancesco Bassi; Gianpietro Semenzato
Journal:  Am J Med       Date:  2004-02-01       Impact factor: 4.965

2.  Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process.

Authors:  J K ORMOND
Journal:  J Urol       Date:  1948-06       Impact factor: 7.450

Review 3.  Idiopathic retroperitoneal fibrosis.

Authors:  N Bullock
Journal:  BMJ       Date:  1988-07-23

4.  Retroperitoneal fibrosis and inapparent obstructive uropathy.

Authors:  A F Lalli
Journal:  Radiology       Date:  1977-02       Impact factor: 11.105

Review 5.  Computed tomography of idiopathic retroperitoneal fibrosis ('periaortitis'): variants, variations, patterns and pitfalls.

Authors:  A P Brooks
Journal:  Clin Radiol       Date:  1990-08       Impact factor: 2.350

Review 6.  Chronic periaortitis: a spectrum of diseases.

Authors:  Augusto Vaglio; Carlo Buzio
Journal:  Curr Opin Rheumatol       Date:  2005-01       Impact factor: 5.006

7.  Retroperitoneal fibrosis treated with methylprednisolon pulse and disease-modifying antirheumatic drugs.

Authors:  M Harreby; T Bilde; P Helin; H H Meyhoff; H Vinterberg; V A Nielsen
Journal:  Scand J Urol Nephrol       Date:  1994-09

8.  The clinical significance of retroperitoneal fibrosis.

Authors:  L Koep; G D Zuidema
Journal:  Surgery       Date:  1977-03       Impact factor: 3.982

9.  High 2-deoxy-2-[18F]fluoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumor.

Authors:  Subhash Chander; Eser Lay Ergun; Harry T Chugani; Diane C Chugani; Csaba Juhasz; Anthony F Shields; Donald W Weaver
Journal:  Mol Imaging Biol       Date:  2002-10       Impact factor: 3.488

Review 10.  Robot-assisted laparoscopic ureterolysis: case report and literature review of the minimally invasive surgical approach.

Authors:  Stéfanie A Seixas-Mikelus; Susan J Marshall; D Dawon Stephens; Aaron Blumenfeld; Eric D Arnone; Khurshid A Guru
Journal:  JSLS       Date:  2010 Apr-Jun       Impact factor: 2.172

View more
  10 in total

1.  Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology.

Authors:  C Alberti
Journal:  G Chir       Date:  2015 Jul-Aug

2.  Idiopathic retroperitoneal fibrosis: clinical features and long-term renal function outcome.

Authors:  Mohamed H Zahran; Yasser Osman; Mohamed A Soltan; Ahmed Elhussein Abolazm; Mostafa K Ghazy; Ahmed M Harraz; Ahmed A Shokeir; Hassan Abol-Enein; Bedeir Ali-El-Dein
Journal:  Int Urol Nephrol       Date:  2017-05-13       Impact factor: 2.370

Review 3.  Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease.

Authors:  Giovanni Maria Rossi; Rossana Rocco; Eugenia Accorsi Buttini; Chiara Marvisi; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2017-01-09       Impact factor: 3.397

4.  [Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports].

Authors:  S B Liu; H Gao; Y C Feng; J Li; T Zhang; L Wan; Y Y Liu; S G Li; C H Luo; X W Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

Review 5.  [New (and old) aspects of retroperitoneal fibrosis].

Authors:  A S Brandt; N M Dreger; E Müller; S Kukuk; S Roth
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

6.  Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of (18)F-FDG-PET/CT and biochemical parameters in patients with renal involvement.

Authors:  Claudia Fofi; Daniela Prosperi; Laura Pettorini; Francescaromana Festuccia; Riccardo Pirisino; Valerio Lanni; Francesco Scopinaro; Giorgio Punzo; Paolo Menè
Journal:  Intern Emerg Med       Date:  2016-03-12       Impact factor: 3.397

7.  Retroperitoneal fibrosis: retrospective descriptive study on clinical features and management.

Authors:  Ann-Sophie Laroche; Robert Z Bell; Sarah Bezzaoucha; Eva Földes; Caroline Lamarche; Michel Vallée
Journal:  Res Rep Urol       Date:  2016-10-26

Review 8.  Retroperitoneal fibrosis - the state-of-the-art.

Authors:  Marta Runowska; Dominik Majewski; Mariusz Puszczewicz
Journal:  Reumatologia       Date:  2016-11-28

9.  Retroperitoneal fibrosis in the era of immunoglobulin G4-related disease.

Authors:  Yoon Kyung Choi; Ji Hyun Yang; Shin Young Ahn; Gang Jee Ko; Se Won Oh; Myung Gyu Kim; Won Yong Cho; Sang Kyung Jo
Journal:  Kidney Res Clin Pract       Date:  2019-03-31

10.  [Retroperitoneal fibrosis at the Ibn Sina University Hospital of Rabat: about 18 cases].

Authors:  Abdoulazizi Bilgo; Moussokoro Hadja Koné; Youssef Lamzaf; Anissa Benjafaar; Amine Saouli; Tarik Karmouni; Khalid El Khader; Abdellatif Koutani; Ahmed Ibn Attya Andaloussi
Journal:  Pan Afr Med J       Date:  2021-02-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.